Cardiovascular events are one of the leading causes of mortality in kidney transplant recipients. Hypertension is the most common comorbidity accompanying chronic kidney disease, with prevalence remaining as high as 90% even after kidney transplantation. It is often poorly controlled. Abnormal blood pressure profiles, such as masked or white-coat hypertension, are also extremely common in these patients. The pathophysiology of blood pressure elevation in kidney transplant recipients is complex and includes transplantation-specific risk factors, which are added to the traditional or chronic kidney disease-related factors. Despite these observations, hypertension management has been an under-researched area in kidney transplantation. Thus, relevant evidence derives either from studies in the general population or from small trials in kidney transplant recipients. Based on the relevant guidelines in the general population, lifestyle modifications should probably be applied as the first step of hypertension management in kidney transplant recipients. The optimal pharmacological management of hypertension in kidney transplant recipients is also not clear. Dihydropyridine calcium channel blockers are commonly used as first line agents because of their lack of adverse effects on the kidney, while other antihypertensive drug classes are under-utilised due to fear of the possible haemodynamic consequences on renal function. This review summarizes the existing data on the pathophysiology, diagnosis, prognostic significance and management of hypertension in kidney transplantation.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
U.S. Renal Data System. USRDS 2019 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethseda, MD, 2019.
Bottomley MJ, Harden PN. Update on the long-term complications of renal transplantation. Br Med Bull. 2013;106:117–34.
Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World J Transplant. 2015;5:183–95.
Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015;87:527–34.
Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, et al. Trends in the causes of death among kidney transplant recipients in the united states (1996–2014). Am J Nephrol. 2018;48:472–81.
Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after kidney transplantation: an analysis by era and time post-transplant. J Am Soc Nephrol. 2020;31:2887–99.
Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010;89:851–7.
Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis. 1993;21:73–8.
Budde K, Waiser J, Fritsche L, Zitzmann J, Schreiber M, Kunz R, et al. Hypertension in patients after renal transplantation. Transpl Proc. 1997;29:209–11.
Campistol JM, Romero R, Paul J, Gutierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant. 2004;19:iii62–6.
Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071–81.
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C. et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–e248.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D. et al. International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57.
J. B. S. Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100:ii1–ii67.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J. et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA . 2014;311:507–20.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337–414.
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136. 2019.
National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. www.nice.org.uk/guidance/cg182. 2014.
National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults. https://www.heartfoundation.org.au/getmedia/c83511ab-835a-4fcf-96f5-88d770582ddc/PRO-167_Hypertension-guideline-2016_WEB.pdf. 2016.
Gago Fraile M, Fernandez Fresnedo G, Gomez-Alamillo C, de Castro SS, Arias M. Clinical and epidemiological characteristics of refractory hypertension in renal transplant patients. Transpl Proc. 2009;41:2132–3.
Kolonko A, Bartmanska M, Slabiak-Blaz N, Kuczera P, Kujawa-Szewieczek A, Ficek R, et al. Arterial stiffness but not endothelial dysfunction is associated with multidrug antihypertensive therapy and nondipper blood pressure pattern in kidney transplant recipients. Med (Baltim). 2018;97:e11870.
Arias M, Fernandez-Fresnedo G, Gago M, Rodrigo E, Gomez-Alamillo C, Toyos C. et al. Clinical characteristics of resistant hypertension in renal transplant patients. Nephrol Dial Transplant. 2012;27:iv36–8.
Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative transplant study. Kidney Int. 1998;53:217–22.
Kooman JP, Christiaans MH, Boots JM, van Der Sande FM, Leunissen KM, van Hooff JP. A comparison between office and ambulatory blood pressure measurements in renal transplant patients with chronic transplant nephropathy. Am J Kidney Dis. 2001;37:1170–6.
Wen KC, Gourishankar S. Evaluating the utility of ambulatory blood pressure monitoring in kidney transplant recipients. Clin Transplant. 2012;26:E465–70.
Ahmed J, Ozorio V, Farrant M, Van Der Merwe W. Ambulatory vs office blood pressure monitoring in renal transplant recipients. J Clin Hypertens (Greenwich). 2015;17:46–50.
Mallamaci F, Tripepi R, Leonardis D, Mafrica A, Versace MC, Provenzano F, et al. Nocturnal hypertension and altered night-day BP profile and atherosclerosis in renal transplant patients. Transplantation .2016;100:2211–8.
Fernandez Fresnedo G, Franco Esteve A, Gomez Huertas E, Cabello Chaves V, Diz Gomez JM, Osorio Moratalla JM, et al. Ambulatory blood pressure monitoring in kidney transplant patients: RETENAL study. Transpl Proc. 2012;44:2601–2.
Kayrak M, Gul EE, Kaya C, Solak Y, Turkmen K, Yazici R, et al. Masked hypertension in renal transplant recipients. Blood Press. 2014;23:47–53.
Cosio FG, Dillon JJ, Falkenhain ME, Tesi RJ, Henry ML, Elkhammas EA, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int. 1995;47:1136–41.
Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283:633–8.
Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13:1084–90.
Mange KC, Feldman HI, Joffe MM, Fa K, Bloom RD. Blood pressure and the survival of renal allografts from living donors. J Am Soc Nephrol. 2004;15:187–93.
Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant. 2004;18:596–604.
Tutone VK, Mark PB, Stewart GA, Tan CC, Rodger RS, Geddes CC, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant. 2005;19:181–92.
Opelz G, Dohler B.Collaborative Transplant S. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5:2725–31.
Ibernon M, Moreso F, Sarrias X, Sarrias M, Grinyo JM, Fernandez-Real JM, et al. Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. Nephrol Dial Transplant. 2012;27:2089–95.
Wadei HM, Amer H, Griffin MD, Taler SJ, Stegall MD, Textor SC. Abnormal circadian blood pressure pattern 1-year after kidney transplantation is associated with subsequent lower glomerular filtration rate in recipients without rejection. J Am Soc Hypertens. 2011;5:39–47.
Mallamaci F, D’Arrigo G, Tripepi R, Leonardis D, Porto G, Testa A, et al. Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. J Hypertens. 2018;36:119–25.
McManus RJ, Caulfield M, Williams B, National Institute for H. Clinical E. NICE hypertension guideline 2011: evidence based evolution. BMJ .2012;344:e181.
Siu AL, USPST Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:778–86.
Mallamaci F, Leonardis D, Tripepi R, Parlongo G, Catalano C, Tripepi G, et al. Sleep disordered breathing in renal transplant patients. Am J Transplant. 2009;9:1373–81.
Molnar MZ, Lazar AS, Lindner A, Fornadi K, Czira ME, Dunai A, et al. Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients. Clin J Am Soc Nephrol. 2010;5:125–32.
Lafranca JA, IJ JN, Betjes MG, et al. mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med. 2015;13:111.
Mourad G, Glyda M, Albano L, Viklicky O, Merville P, Tyden G, et al. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial. Transplantation. 2017;101:1924–34.
Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, et al. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015;26:1248–60.
Aziz F, Clark D, Garg N, Mandelbrot D, Djamali A. Hypertension guidelines: how do they apply to kidney transplant recipients. Transpl Rev (Orlando). 2018;32:225–33.
Mallamaci F, Tripepi R, D’Arrigo G, Panuccio V, Parlongo G, Caridi G, et al. Sleep-disordered breathing and 24-hour ambulatory blood pressure monitoring in renal transplant patients: longitudinal study. J Am Heart Assoc. 2020;9:e016237.
Workeneh B, Moore LW, Nolte Fong JV, Shypailo R, Gaber AO, Mitch WE. Successful kidney transplantation is associated with weight gain from truncal obesity and insulin resistance. J Ren Nutr. 2019;29:548–55.
Hornum M, Lindahl JP, von Zur-Muhlen B, Jenssen T, Feldt-Rasmussen B. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl Int. 2013;26:1049–60.
Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease: causes and consequences. Heart. 2010;96:817–23.
Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis. 2012;223:86–94.
Yabu JM, Winkelmayer WC. Posttransplantation anemia: mechanisms and management. Clin J Am Soc Nephrol. 2011;6:1794–801.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74:120–31.
Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31:541–50.
Faucon AL, Flamant M, Metzger M, Boffa JJ, Haymann JP, Houillier P, et al. Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney Int. 2019;96:1020–9.
Chan W, Bosch JA, Jones D, McTernan PG, Inston N, Moore S, et al. Hypervolemia and blood pressure in prevalent kidney transplant recipients. Transplantation .2014;98:320–7.
Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568–76.
Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanisms. Int J Mol Sci. 2017;18:1682–99.
Kasiske BL. Possible causes and consequences of hypertension in stable renal transplant patients. Transplantation.1987;44:639–43.
Gazdar AF, Dammin GJ. Neural degeneration and regeneration in human renal transplants. N. Engl J Med. 1970;283:222–4.
Klein IH, Abrahams AC, van Ede T, Oey PL, Ligtenberg G, Blankestijn PJ. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens. 2010;28:1928–34.
Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant. 2007;22:1963–8.
Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16:1501–11.
Grisk O, Steinbach AC, Ciecholewski S, Schluter T, Kloting I, Schmidt H, et al. Multidrug resistance-related protein 2 genotype of the donor affects kidney graft function. Pharmacogenet Genomics. 2009;19:276–88.
Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11:1025–30.
Brenner BM, Milford EL. Nephron underdosing: a programmed cause of chronic renal allograft failure. Am J Kidney Dis. 1993;21:66–72.
Barton RH, Waterman D, Bonner FW, Holmes E, Clarke R, Procardis C, et al. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol Biosyst. 2010;6:215–24.
Gjertson DW. Explainable variation in renal transplant outcomes: a comparison of standard and expanded criteria donors. Clin Transpl. 2004;189:303–14.
Blanca L, Jimenez T, Cabello M, Sola E, Gutierrez C, Burgos D, et al. Cardiovascular risk in recipients with kidney transplants from expanded criteria donors. Transpl Proc. 2012;44:2579–81.
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216–29.
Baum M, Moe OW. Glucocorticoid-mediated hypertension: does the vascular smooth muscle hold all the answers? J Am Soc Nephrol. 2008;19:1251–3.
Wen C, Li M, Whitworth JA. Role of nitric oxide in adrenocorticotrophin-induced hypertension: L-arginine effects reversed by N-nitro-L-arginine. Clin Exp Pharm Physiol. 2000;27:887–90.
Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res. 1996;19:1–8.
Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG. Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol. 1976;5:123–7.
McDonald FD, Horensten ML, Mayor GB, Turcotte JG, Selezinka W, Schork MA. Effect of alternate-day steroids on renal transplant function. A controlled study. Nephron. 1976;17:415–29.
Jackson SH, Beevers DG, Myers K. Does long-term low-dose corticosteroid therapy cause hypertension?. Clin Sci (Lond). 1981;61:381s–3s.
Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825–32.
Hamawy MM. Molecular actions of calcineurin inhibitors. Drug N. Perspect. 2003;16:277–82.
Frist WH, Stinson EB, Oyer PE, Baldwin JC, Shumway NE. Long-term hemodynamic results after cardiac transplantation. J Thorac Cardiovasc Surg. 1987;94:685–93.
Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens. 1991;4:468–71.
Perico N, Ruggenenti P, Gaspari F, Mosconi L, Benigni A, Amuchastegui CS, et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation .1992;54:56–60.
Dello Strologo L, Massella L, Rizzoni G. Cyclosporine-induced transient renal hypoperfusion in adolescent transplant recipients. Pediatr Nephrol. 1996;10:81–3.
Perico N, Detcheva A, Khalil EI, Remuzzi G. Cyclosporine induces glomerulosclerosis: three-dimensional definition of the lesions in a rat model of renal transplant. Kidney Int. 1996;49:1283–8.
Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest 1994;93:2244–50.
Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–18.
Gardiner SM, March JE, Kemp PA, Fallgren B, Bennett T. Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. Br J Pharmacol. 2004;141:634–43.
Esteva-Font C, Ars E, Guillen-Gomez E, Campistol JM, Sanz L, Jimenez W, et al. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant. 2007;22:2810–6.
Hoorn EJ, Walsh SB, Unwin RJ, Ellison DH. Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity. J Hypertens. 2012;30:832–3.
Hoorn EJ, Walsh SB, McCormick JA, Furstenberg A, Yang CL, Roeschel T, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304–9.
Ferro CJ, Savage T, Pinder SJ, Tomson CR. Central aortic pressure augmentation in stable renal transplant recipients. Kidney Int. 2002;62:166–71.
Morales JM, Dominguez-Gil B. Impact of tacrolimus and mycophenolate mofetil combination on cardiovascular risk profile after kidney transplantation. J Am Soc Nephrol. 2006;17:S296–303.
Kramer BK, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Ortuno J, et al. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant. 2008;23:2386–92.
Margreiter R. European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study G. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet .2002;359:741–6.
Seibert F, Behrendt C, Schmidt S, van der Giet M, Zidek W, Westhoff TH. Differential effects of cyclosporine and tacrolimus on arterial function. Transpl Int. 2011;24:708–15.
Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35:181–8.
Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant. 2012;27:850–7.
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl J Med. 2007;357:2562–75.
Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014; CD010699
Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl. 2002;62:S81–87.
Fervenza FC, Lafayette RA, Alfrey EJ, Petersen J. Renal artery stenosis in kidney transplants. Am J Kidney Dis. 1998;31:142–8.
Rajan DK, Stavropoulos SW, Shlansky-Goldberg RD. Management of transplant renal artery stenosis. Semin Interv Radiol. 2004;21:259–69.
Baird DP, Williams J, Petrie M, James JR. Transplant Renal Artery Stenosis. KI Reports. In press.
Ngo AT, Markar SR, De Lijster MS, Duncan N, Taube D, Hamady MS. A systematic review of outcomes following percutaneous transluminal angioplasty and stenting in the treatment of transplant renal artery stenosis. Cardiovasc Interv Radiol. 2015;38:1573–88.
Becker BN, Odorico JS, Becker YT, Leverson G, McDermott JC, Grist T, et al. Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. Clin Transplant. 1999;13:349–55.
Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 2013;13:2567–76.
Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl J Med. 2005;352:558–69.
Kelsch R, Everding AS, Kuwertz-Broking E, Brand E, Spriewald BM, Sibrowski W, et al. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation. 2011;92:e57–59.
Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, et al. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart. 2011;97:479–84.
Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int. 2011;24:523–33.
KDIGO CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;3:1–150.
Kuningas K, Driscoll J, Mair R, Smith H, Dutton M, Day E, et al. Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients: a randomized controlled trial. Transplantation. 2020;104:1491–9.
Grzesk G, Wicinski M, Malinowski B, Grzesk E, Manysiak S, Odrowaz-Sypniewska G, et al. Calcium blockers inhibit cyclosporine A-induced hyperreactivity of vascular smooth muscle cells. Mol Med Rep. 2012;5:1469–74.
Cross NB, Webster AC, Masson P, O’Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev. 2009; CD003598.
Pisano A, Bolignano D, Mallamaci F, D’Arrigo G, Halimi JM, Persu A, et al. Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2020;35:878–87.
Aftab W, Varadarajan P, Rasool S, Kore A, Pai RG. Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. J Am Heart Assoc. 2013;2:e000091.
Tantisattamo E, Molnar MZ, Ho BT, Reddy UG, Dafoe DC, Ichii H, et al. Approach and management of hypertension after kidney transplantation. Front Med (Lausanne). 2020;7:229.
Taber DJ, Srinivas TM, Pilch NA, Meadows HB, Fleming JN, McGillicuddy JW, et al. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? Am J Nephrol. 2013;38:285–91.
Moes AD, Hesselink DA, van den Meiracker AH, Zietse R, Hoorn EJ. Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial. Am J Kidney Dis. 2017;69:796–804.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.
Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34:208–30.
Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care. 2019;42:1067–74.
Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant. 2019;19:907–19.
Onesti G, Swartz C, Ramirez O, Brest AN. Bilateral nephrectomy for control of hypertension in uremia. Trans Am Soc Artif Intern Organs. 1968;14:361–6.
Cohen SL. Hypertension in renal transplant recipients: role of bilateral nephrectomy. Br Med J. 1973;3:78–81.
Lerman MJ, Hinton S, Aronoff R. Bilateral native nephrectomy for refractory hypertension in kidney transplant and kidney pancreas transplant patients. Int J Surg Case Rep. 2015;15:127–9.
Ott C, Schmieder RE. Invasive treatment of resistant hypertension: present and future. Curr Hypertens Rep. 2014;16:488.
Gajulapalli RD, Chahine J, Rader F, Aneja A. Procedures and devices to treat resistant hypertension in chronic kidney disease. Cleve Clin J Med. 2020;87:435–43.
Dobrowolski LC, Bemelman FJ, Ten Berge IJ, van den Born BJ, Reekers JA, Krediet CT. Renal denervation of the native kidneys for drug-resistant hypertension after kidney transplantation. Clin Kidney J. 2015;8:79–81.
Halimi JM, Persu A, Sarafidis PA, Burnier M, Abramowicz D, Sautenet B, et al. Optimizing hypertension management in renal transplantation: a call to action. Nephrol Dial Transplant. 2017;32:1959–62.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Loutradis, C., Sarafidis, P., Marinaki, S. et al. Role of hypertension in kidney transplant recipients. J Hum Hypertens (2021). https://doi.org/10.1038/s41371-021-00540-5